[HTML][HTML] The role of proteomics and phosphoproteomics in the discovery of therapeutic targets and biomarkers in acquired EGFR-TKI-resistant non-small cell lung …

S Moonmuang, A Tantraworasin, S Orrapin… - International Journal of …, 2023 - mdpi.com
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

[PDF][PDF] The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin, S Orrapin… - Int. J. Mol …, 2023 - pdfs.semanticscholar.org
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin, S Orrapin… - … Journal of Molecular …, 2023 - europepmc.org
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

[HTML][HTML] The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell …

S Moonmuang, A Tantraworasin, S Orrapin… - … Journal of Molecular …, 2023 - ncbi.nlm.nih.gov
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin… - International …, 2023 - search.ebscohost.com
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin… - International …, 2023 - search.proquest.com
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin… - International …, 2023 - pubmed.ncbi.nlm.nih.gov
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung …

S Moonmuang, A Tantraworasin, S Orrapin… - … Journal of Molecular …, 2023 - europepmc.org
The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the
treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded …